Home › NDC Lookup › RxCUI directory › RxCUI 2721468

{7 (futibatinib 16 MG Oral Tablet [Lytgobi]) / 7 (futibatinib 4 MG Oral Tablet [Lytgobi])... — RxCUI 2721468

RxNorm drug concept · Brand name pack
RxCUI 2721468 Brand name pack · BPCK ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2721468
Official name{7 (futibatinib 16 MG Oral Tablet [Lytgobi]) / 7 (futibatinib 4 MG Oral Tablet [Lytgobi]) } Pack [Lytgobi 20 MG Daily Dose - 4 MG (7), 16 MG (7)]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known asLytgobi 20 MG Daily Dose - 4 MG (7), 16 MG (7)
FDA products mapped3
Package NDCs mapped5
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Futibatinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Lytgobi is treating a specific type of bile duct cancer called intrahepatic cholangiocarcinoma — 'intrahepatic' means the cancer started inside the liver, in the bile ducts there....
  • What exactly is Lytgobi treating — can you explain it in plain language?
  • You can take Lytgobi with or without food, so meals don't need to be planned around it. What does matter is consistency — try to take it at roughly the same time each day. If you h...
  • Do I have to take it at a specific time of day, and does it matter if I eat first?
📖 Read our full Futibatinib guide →

🕸️ Concept Web — How {7 (futibatinib 16 MG Oral Tablet [Lytgobi]) / 7... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {7 (futibatinib 16 MG Oral Tablet [Lytgobi]) / 7 (futibatinib 4 MG Oral Tablet [Lytgobi]) } Pack [Lytgobi 20 MG Daily Dose - 4 MG (7), 16 MG (7)] RxCUI 2721468

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Futibatinib 2628190
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Lytgobi 2628196
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Futibatinib Oral Tablet 2628194
    • Futibatinib Oral Product 2628192
    • Futibatinib Pill 2628193
    • Futibatinib Oral Tablet [Lytgobi] 2628200
    • Lytgobi Oral Product 2628198
    • Lytgobi Pill 2628199
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 8

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

3 products · 5 package NDCs
5 package NDCs map to RxCUI 2721468 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
64842-0120-04 1 BLISTER PACK in 1 CARTON (64842-0120-4) / 21 TABLET in 1... LYTGOBI TAIHO PHARMACEUTICAL CO., LTD. 2023-02-03
64842-0120-05 1 BLISTER PACK in 1 CARTON (64842-0120-5) / 28 TABLET in 1... LYTGOBI TAIHO PHARMACEUTICAL CO., LTD. 2023-02-03
64842-0120-06 1 BLISTER PACK in 1 CARTON (64842-0120-6) / 35 TABLET in 1... LYTGOBI TAIHO PHARMACEUTICAL CO., LTD. 2023-02-03
64842-0127-07 1 BLISTER PACK in 1 CARTON (64842-0127-7) / 7 TABLET in 1 B... LYTGOBI TAIHO PHARMACEUTICAL CO., LTD. 2026-06-01
64842-0128-08 1 BLISTER PACK in 1 CARTON (64842-0128-8) / 1 KIT in 1 BLIS... LYTGOBI TAIHO PHARMACEUTICAL CO., LTD. 2026-06-01
Observed labelers: TAIHO PHARMACEUTICAL CO., LTD. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.